Compumedics Ltd
Compumedics Delivers Record FY26 Revenue as SaaS Growth Accelerates
Compumedics posts FY26 revenue of $60.3m (+18%), SaaS up ~70% led by Somfit/Nexus 360; MEG delays temper guidance, FY27 targets double-digit growth.
Compumedics Looks to Turn the Corner after Record Sales And Growth in FY25
Compumedics (ASX: CMP) has marked a strategic turning point in its development after posting record sales and profitable growth for the 2025 financial year. The company racked up $63.4 million in sales for the period, representing a growth of 22% on the previous year. Its EBITDA increased to approximately $3m, returning Compumedics to profitability and […]
Compumedics reaches $20m in Chinese MEG sales with latest university contract
Brain research technologies specialist Compumedics (ASX: CMP) has reached $20 million in sales for its magnetoencephalography (MEG) system in China. The latest $5.7m contract from Hangzhou Normal University follows the successful installation of a MEG system at Tianjin Normal University and further orders from Tsinghua and Tianjin universities. MEG is a neuroimaging technique for mapping […]
Compumedics eyes US market with Somfit sleep diagnostic device
Brain research technology specialist Compumedics (ASX: CMP) has achieved a major breakthrough with the planned distribution of its Somfit sleep assist system, with the Food & Drug Administration (FDA) clearing the device to be marketed in the United States. Compumedics is targeting the multi-million dollar sleep market in the US with the Somfit technology, which […]